Majocchi S, et al. | 2025, January 6 | Light Chain Bioscience
https://pubmed.ncbi.nlm.nih.gov/34127852/
Research summary
This study introduces NI-3201, a bispecific antibody designed to simultaneously bind PD-L1 and CD28, providing PD-L1-dependent co-stimulation to T cells. The research evaluates NI-3201's potential to enhance anti-tumor immunity by activating T cells within the tumor microenvironment.
Key outcome of the study
NI-3201 demonstrated significant anti-tumor activity by enhancing T cell activation in a PD-L1-dependent manner, leading to improved tumor control in preclinical models. The bispecific antibody exhibited a favorable safety profile, indicating its potential as a novel cancer immunotherapy.
Mouse model generated by genOway
The study utilized a humanized CD28 (hCD28) knock-in mouse model developed by genOway, allowing for the assessment of CD28-targeting therapeutics in a fully immunocompetent system.
NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Get in touch about
Let us know how we can help
Scientific excellence
From model design to experimental results
Featured in 600+ scientific articles
Collaborative approach
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Robust validation data on catalog models
Generated with biopharma partners and in-house
Innovative technologies
and guaranteed freedom to operate
Easy access to models
Models with certified health status from professional breeders in US and Europe